Livio Françoise, Buclin Thierry, Biollaz Jérôme
Division de pharmacologie et toxicologie cliniques, Hôpital de Beaumont, CHUV, 1011 Lausanne.
Rev Med Suisse. 2007 Jan 24;3(95):238-42.
While 2006 did not record as many upsetting revelations of adverse drug reactions as the previous few years, still some data have been produced, which modulate the safety profile of drugs and deserve the attention of the prescribers: cardiovascular events under erythropoietins, macular oedema under rosiglitazone, vascular and renal complications of aprotinine, drawbacks of long-term linezolide administration, intracranial haemorrhage under tipranavir, anyphylaxis with pegaptanib, cardiototoxicity of imatinib, lymphomas with infliximab, bone pain and aches under bisphosphonates, cardiovascular events related to methylphenidate, congenital anomalies ascribed to paroxetine and lamotrigine, neonatal pulmonary hypertension related to serotonine reuptake inhibitors, infantile respiratory depression under promethazine.
尽管2006年记录的药物不良反应令人不安的披露事件不如前几年多，但仍有一些数据产生，这些数据改变了药物的安全性概况，值得开处方者关注：促红细胞生成素下的心血管事件、罗格列酮下的黄斑水肿、抑肽酶的血管和肾脏并发症、长期使用利奈唑胺的缺点、替拉那韦下的颅内出血、培加他尼引起的过敏反应、伊马替尼的心脏毒性、英夫利昔单抗引起的淋巴瘤、双膦酸盐下的骨痛、与哌甲酯相关的心血管事件、归因于帕罗西汀和拉莫三嗪的先天性异常、与血清素再摄取抑制剂相关的新生儿肺动脉高压、异丙嗪下的婴儿呼吸抑制。
